Cytomegalovirus gB Antibody
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-06076
Conjugate
Catalog #
Key Product Details
Species Reactivity
Cytomegalovirus
Applications
ELISA
Label
Unconjugated
Antibody Source
Polyclonal Rabbit IgG
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Produced in rabbits immunized with purified, recombinant Human Cytomegalovirus gB (Accession#: AAA45920.1) extracellular domain (Met 1-Lys 700) linked with the cytoplasmic domain (Arg 777-Val 907)
Clonality
Polyclonal
Host
Rabbit
Isotype
IgG
Description
This antibody can be stored at 2C-8C for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20C to -80C. Avoid repeated freeze-thaw cycles.
Applications for Cytomegalovirus gB Antibody
Application
Recommended Usage
ELISA
1:5000-1:10000
Formulation, Preparation, and Storage
Purification
Antigen and protein A Affinity-purified
Formulation
0.2 um filtered solution in PBS
Preservative
No Preservative
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: Cytomegalovirus gB
Cytomegalovirus is a common virus, infecting ~60% of adults in developed countries and over 90% in developing countries, as indicated by presence of specific IgG antibodies (2-4). Although a majority of people infected remain asymptomatic, immunocompromised people, organ transplant recipients, and fetuses and newborns are more susceptible to HCMV-associated diseases (1-4). Annually, up to 2% of newborns are born with HCMV, making it the most common congenital infection (2-4). Cytomegalovirus is known to cause sensorineural hearing loss (SNHL), mental retardation, chorioretinitis, skin lesions, as well as end organ disease (3,5). There are a few CMV therapeutics approved by FDA including valganciclovir and letermovir; however, despite some benefits, there is the need for new antivirals and combination therapies (5). Potential new treatment options include monoclonal antibodies and sirtuins (5).
References
1. Connolly SA, Jardetzky TS, Longnecker R. The structural basis of herpesvirus entry. Nat Rev Microbiol. 2021;19(2):110-121. https://doi.org/10.1038/s41579-020-00448-w
2. Griffiths P, Reeves M. Pathogenesis of human cytomegalovirus in the immunocompromised host. Nat Rev Microbiol. 2021;19(12):759-773. https://doi.org/10.1038/s41579-021-00582-z
3. Krstanovic F, Britt WJ, Jonjic S, Brizic I. Cytomegalovirus Infection and Inflammation in Developing Brain. Viruses. 2021;13(6):1078. Published 2021 Jun 4. https://doi.org/10.3390/v13061078
4. Griffiths P, Baraniak I, Reeves M. The pathogenesis of human cytomegalovirus. J Pathol. 2015;235(2):288-297. https://doi.org/10.1002/path.4437
5. Acosta E, Bowlin T, Brooks J, et al. Advances in the Development of Therapeutics for Cytomegalovirus Infections. J Infect Dis. 2020;221(Suppl 1):S32-S44. https://doi.org/10.1093/infdis/jiz493
Alternate Names
CMV, CMV glycoprotein B, CMV glycoprotein GP55, Cytomegalovirus glycoprotein GP55, gB, Glycoprotein B, Glycoprotein GP55, HCMV, HCMV glycoprotein B, HCMV glycoprotein GP55, HHV 5 glycoprotein B, HHV 5 glycoprotein GP55, HHV5 glycoprotein B, HHV5 glycoprotein GP55, Human herpesvirus 5 glycoprotein B, Human herpesvirus 5 glycoprotein GP55, UL55
Additional Cytomegalovirus gB Products
Product Documents for Cytomegalovirus gB Antibody
Product Specific Notices for Cytomegalovirus gB Antibody
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...